Biohaven's acute migraine candidate meets in Phase III

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) said Monday that rimegepant (formerly BHV-3000) met the co-primary endpoints in a pair of Phase III trials to treat acute migraine. The company plans to submit an NDA to FDA in 2019

Read the full 381 word article

User Sign In